MedTrace Logo

Platform-based Mild Cognitive Impairment (MCI) Trial

NCT03987464 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2022-02-25

No results posted yet for this study

Summary

The process of receiving a diagnosis of mild cognitive impairment (MCI) is recognized to induce behavioral responses that can be either adaptive or maladaptive. Five specific areas of concern have been identified, including: 1) failure to plan for future decline, decreased compliance and interaction with medical care providers, 3) decreased confidence and reduced social engagement, 4) increased physical limitations and 5) decreased medication compliance. In this pilot study, participants with MCI and their study partners will participate in behavioral interventions (primarily training workshops and classes) targeting each of these five areas of potential maladaptive behaviors.

Conditions

Interventions

BEHAVIORAL

Planning for the Future

This intervention will include attending an advance directives meeting, a living arrangements workshop, and a psychosocial education training workshop.

BEHAVIORAL

Enhanced Medical Engagement

This intervention includes creating a health portfolio, health record access training, and a medical engagement workshop

BEHAVIORAL

Confidence Building and Social Engagement

This intervention includes mindfulness training, a pre-experience training techniques workshop and a memory strategies class.

BEHAVIORAL

Physical Intervention

This intervention includes physical/occupational therapy (PT/OT), a home safety assessment, and an independent exercise program.

BEHAVIORAL

Medical Adherence

This intervention includes using automated pillboxes to ensure medication compliance, optimizing appropriate medication use through review, and engaging with memory medications via class.

Sponsors & Collaborators

  • Allison Gibson

    lead OTHER

Principal Investigators

  • Allison Gibson, PhD, MSW · University of Kentucky

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2021-12-14
Completion
2021-12-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03987464 on ClinicalTrials.gov